Figure 2.

The impact of V‐domain Ig suppressor of T cell activation (VISTA) blockade on the tumor microenvironment profile. Anti‐VISTA treatment improves T cell priming and infiltration while impeding myeloid infiltration. Additionally, anti‐VISTA appears to reprogram myeloid cells, reducing expression of suppressive mediators such as arginase 1 and reactive oxygen species (ROS), and improving expression of co‐stimulatory molecules. This can result in improved T cell effector function and anti‐tumor immunity.